Innocan Pharma
In den Zahlenveröffentlichungen des Unternehmens steht das etwas anders drin als in deinen Beitrag und das ist leider die ungeschminkte Wahrheit:
Innocan has experienced net losses in every period since its inception in 2018. It incurred net losses of $230,000 and $1,454,000 for the three-month period ended March 31, 2025, and 2024, respectively. As of March 31, 2025 and December 31, 2024, it had an accumulated deficit of $35,491,000 and $34,908,000, respectively. Innocan anticipate that it will continue to incur significant losses for the foreseeable future as its operating expenses and capital expenditure increase substantially due to its continued investment in its research and development activities and as it hires additional employees over the coming years